Skip to main content
ASPHO Logo
Menu Journal My Account Contact Join/Renew
Login
  • Meetings & Events
    • Conference
      • 2021 Conference
        • Back to Meetings & Events
        • 2021 Conference Overview
        • Schedule of Events
        • PTCTC Schedule
        • Plan Your Experience
        • Registration Rates
        • Register Yourself
        • Register A Colleague
        • Cancellation Policy
        • Continuing Education
        • Sponsors
        • Faculty
        • Conference Planning Committee
        • Virtual Support and Advertising
      • Meetings Archive
      • Press | 2018 Conference
      • 2018 Call for Papers and Posters
        • Back to Meetings
        • 2019 Conference
        • Schedule of Events
        • Registration Rates
        • Conference Planning Committee
        • Conference Hotel and Travel
        • Faculty
        • 2019 Call for Papers and Posters
        • Continuing Education
        • PBMTC
        • Accepted Papers and Posters
        • Corporate Symposia
        • MOC Opportunities
        • App - Thank you for Attending
        • 2019 Attendee List
      • 2019 Call for Workshops
      • 2018 Conference
        • Schedule of Events
        • Accepted Papers and Posters
      • 2016 Annual Meeting
        • Overview
        • Attendee List
        • ASPHO Virtual Bag
        • Corporate Forum Symposia/Education Theaters
        • Accepted Papers and Posters
          • Accepted A-G
          • Accepted H-M
          • Accepted N-Z
          • 2016 Searchable Abstract Database
        • Exhibit Hall
        • Sponsors
        • Annual Meeting Brochure
        • 2017 Call for Workshops
        • Virtual Bag
        • Schedule of Events
        • Continuing Education
        • Attendee List
        • 2017 Searchable Abstract Database
        • Accepted Papers and Posters
        • Corporate Forum Symposia/Education Theater
        • Travel
        • Program Committee
        • Commercial Support
        • Exhibit with ASPHO
        • Commercial Support
          • Commercial Support
            • Commercial Support
            • Commercial Support
            • Industry Relations Council
            • Advertising
            • Exhibiting and Advertising
              • Exhibit and Advertising
              • Commercial Support
    • Review Course
      • Anderson 2019
      • McClain 2019
      • Adams 2019
      • Moran 2019
      • Effinger 2019
      • 2021 Review Course
      • Schedule
      • Learning Objectives and CME
      • Faculty
      • Planning Committee
      • Review Course Archive
      • Fangusaro 2021
      • Brown 2021
      • Young 2021
      • Harker-Murray 2021
      • Effinger 2021
      • Pai 2021
      • Grace 2021
      • Rogers 2021
      • Anderson 2021
      • Powers 2021
      • McClain 2021
      • Neunert 2021
      • Fleming 2021
      • Mullen 2021
      • Pommert 2021
      • Meade 2021
      • Greengard 2021
      • Fox 2021
      • Bercovitz 2021
      • Brock 2021
      • Adams 2021
      • Loh 2021
      • O'Brien 2021
      • Walterhouse 2021
      • Pulsipher 2021
      • Oberley 2021
      • Rodriguez-Galindo 2021
      • Kesselheim 2021
      • Frei-Jones 2021
      • Allen 2021
      • 2015 Online Review Course CME Certificates
      • 2019 Planning Committee
      • 2019 Schedule
      • 2019 Travel
      • 2019 Review Course Early Career
      • 2019 Review Course Directors
        • 2019 Review Course Faculty
      • Oberley 2019
      • O'Brien 2019
      • Pai 2019
      • Pulsipher 2019
      • Rodriguez-Galindo 2019
      • Rogers 2019
      • Walterhouse 2019
      • Young 2019
      • Park 2019
      • Malec 2019
      • Evaluations
      • Brown 2019
      • Allen 2019
      • Fangusaro 2019
      • Fleming 2019
      • Frei-Jones 2019
      • Grace 2019
      • Harker-Murray 2019
      • Heeney 2019
      • Kesselheim 2019
      • Loh 2019
      • Mascarenhas 2019
      • Neunert 2019
    • Events Calendar
  • Knowledge Center
    • Products
      • Recordings
      • Webinars
      • ASPHOcast
      • 2020 Compensation Survey
    • Online Review Course
    • Pediatric Blood & Cancer
      • Access Journal
      • Online Access Instructions
    • ASPHO eNews
      • August 2015 Enews
      • June 2015 Enews
      • April 2015 Enews
      • February 2015 Enews
      • December 2014 Enews
      • October 2014 Enews
      • August 2014 Enews
      • June 2014 Enews
      • April 2014 Enews
      • February 2014 Enews
      • December 2013 Enews
      • October 2013 Enews
      • August 2013 Enews
      • June 2013 Enews
      • April 2013 Enews
      • February 2013 Enews
      • October 2014 Enews
      • October 2015 Enews
      • December 2015 Enews
      • February 2016 Enews
      • April 2016 Enews
      • June 2016 Enews
        • DSIG Student Registration
      • August 2016 Enews
      • October 2016 Enews
      • December 2016 Enews
      • February 2017 Enews
      • April 2017 Enews
      • June 2017 Enews
      • August 2017 Enews
      • October 2017 Enews
      • December 2017 Enews
      • February 2018 Enews
      • April 2018 Enews
      • June 2018 Enews
      • August 2018 eNews
      • October 2018 eNews
      • February 2019 eNews
      • Member Insights: eNews 2018 Highlights
      • April 2019 eNews
      • June 2019 eNews
      • August 2019 eNews
      • October 2019 eNews
      • December 2019 eNews
    • Pediatric Blood & Cancer - Call for Applications for Deputy Editor
    • October 2015 Enews
    • Advocacy Sample
    • Health Policy & Advocacy
      • 2016 August Advocacy Brief
      • 2016 December Advocacy Brief
      • 2017 February Advocacy Brief
      • 2017 May Advocacy Brief
      • 2017 September Advocacy Brief
      • 2017 November Advocacy Brief
      • 2018 Advocacy Brief - March
      • Contact Your Members of Congress
      • 2018-Advocacy-Brief-June
      • 2018-Advocacy-Brief-September
      • Advocacy Brief December 2018
      • 2019 Advocacy Brief - March
      • March 2019 Advocacy Brief
      • June 2019 Advocacy Brief
      • September 2019 Advocacy Brief
    • 2017 Workforce Survey Report
    • Help Fund the STAT Act
    • Practice and Quality
    • Choosing Wisely®
    • COVID–19 Resources
  • Career Development
    • Mentoring
      • Enroll as a Mentee
      • Enroll as a Mentor
    • Awards
      • Distinguished Career Award
      • Oski Memorial Lectureship
      • International Travel Awards
      • Arceci Innovation Award
      • Buchanan Lectureship
      • Young Investigator Award
      • Young Investigator Form
      • EC Travel Stipend Form
      • Early Career Travel Stipend
      • Advanced Practice Professional Award
      • Clinician Educator Award
      • Clinician Educator Award
      • Northwestern Mutual Award for Excellence in Childhood Cancer Survivorship
    • Career Center
    • Fellowship Resources
      • Post-PHO Fellowship Program Directory
      • Fellowship Program Directors' Resources
    • Certification
      • Continuing Medical Education
      • advocating for moc
      • ABP MOC Letter Nov 2015
      • 2019 ABP Hematology/Oncology Content Outline
    • 2019 ASPHO Award Recipients
    • Workforce
  • Membership
    • Who Belongs
    • Benefits
    • Join Us
    • Renew
    • Membership Application
    • Fellows Group Application
    • Member Community
    • Special Interest Groups
      • Adolescent and Young Adult SIG
      • Advanced Practice Provider SIG
      • Cancer Predisposition SIG
      • Clinical Immunology SIG
      • Diversity SIG
        • 2017 DSIG Travel Award
      • Global Hem Onc SIG
      • Hemoglobinopathy SIG
      • Informatics, Innovation and Entrepreneurship SIG
      • Integrative Pediatric Hematology/Oncology SIG
      • Palliative Care SIG
      • Physician Scientist SIG
      • Quality Improvement and Patient Safety SIG
      • Small Program SIG
      • Vascular Anomalies SIG
      • Clinical Immunology SIG Webinar
      • Well-Being SIG
    • Enriching the Future
      • ETF Donors
      • ETF FAQ
      • ETF Programs
      • ETF Award Recipients
      • Donate
    • Stay Connected with ASPHO
    • New Member
    • Trainee Membership Level
  • About
    • Governance
      • 2017 Election Nominations
      • 2019 Board and Nominating Committee members
    • Strategic Plan
      • Leadership Domain
      • Education Domain
      • Career Domain
      • Administration Domain
    • Committees
      • Early Career Council
    • Policies
      • Advertising Sponsorship
      • Support of CME
      • Committee Policies, Responsibilities, and Resources
      • Conflict of Interest and Disclosure for Volunteers
      • Distinguished Career Award Eligibility Criteria
      • Diversity Statement
      • Investment
      • Member Mailing List
      • Oski Eligibility Criteria
      • Presidential Stipend
      • Records Retention
      • Reserve Fund
      • Reviews and Endorsements
      • Speaker Reimbursement
      • Surveying Members
      • Whistleblower
      • Workshop Session
      • Young Investigator Award
      • Early Career Travel Stipend
      • Buchanan Lectureship Eligibility
    • Terms of Use
    • Contact Us
    • 2016 Election Nominations
    • 2015 Election Candidates
    • FDA Approves Dinutuximab
    • Q&A Amy Billett
    • Fund Raising Policy
    • Support and Advertising
      • Sponsorship
      • Exhibit
      • Advertising
      • Industry Relations Council
    • Diversity & Inclusion
  • 2017 Annual Meeting Session Recordings
  • 2018 Annual Meeting Session Recordings
  • George R. Buchanan Lectureship Award Presentation
  • Cancer Predispositions in Clinical Practice
  • Evidence and Equipoise in Pediatric Thrombosis - Updates from Randomized Controlled Trials
  • Playing on Our Strengths - Developing Interprofessional Teams in Pediatric Hematology-Oncology
  • Providing Optimal Pediatric Palliative Care: Overcoming the Barriers
  • When in Quebec, Do What the Quebecers Do (Part Deux) - It's All About Platelets!
  • Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Pediatric Patients with ALL in the era of Tyrosine Kinase Inhibitors, Novel Immunotherapies and 'MRD Status'
  • Award Presentations
  • Hemophilic Arthropathy, More Than Meets the Eye: Advances in Early Disease Detection from Clinical Tools to Musculoskeletal Imaging
  • ZFNs, CrispR/Cas9 and TALENS- Oh My!
  • Collaboration in the Treatment of Liver Tumors
  • Leukemia
  • Solid Tumors/Lymphoma
  • Hematology I
  • Beyond Antibodies and CAR T Cells: Challenges and Opportunities in Manipulating the Pediatric Cancer Immunome
  • Blood Clots in Sick Kids: A critical mini-review of venous thrombo-embolism in selected high-risk pediatric populations
  • It's not just about Diversity: Improving the Outcomes for All by Moving toward Equity
  • Children's Oncology Group (COG)
  • Outcomes Research
  • Social Media: The Good, The Bad, and Beyond
  • Sickle Cell Disease in the AYA population: Management Challenges for the Pediatric Hematologist
  • Molecularly Defined Rare Pediatric Sarcomas: An Update for the General Oncologist
  • Mechanisms of Tumor Microenvironment Immune Mediated Resistance and Methods of Therapeutic Circumvention
  • Behind the Scenes at Pediatric Blood & Cancer: Everything You Always Wanted to Know About Getting Published
  • New Insights in Inherited Hematologic Diseases
  • Changing Workforce of Pediatric Hematology/Oncology
  • New Diagnostic and Therapeutic Approaches of Opportunistic (Viral/Fungal) Infections in the Pediatric Cancer Patient
  • New Mutations and Targeted Therapies in Langerhans Cell Histiocytosis
  • Physician, Sustain Thyself: Building Resilience to Prevent Burnout
  • Practicing Precision in Pediatric Oncology: Three Perspectives
  • What's Happening in DC? A Look at ASPHO Advocacy Efforts
  • Critical Care of the Immunocompromised Pediatric Hematology/Oncology Patient
  • Brain Tumors
  • Hematology II
  • Sponsor, Exhibit, and Advertise
    • Sponsorship
    • Exhibits
    • Advertising
    • Industry Relations Council
    • Exhibits Adveritising
    • Commercial Support
  • Ward Testing OSE
  • 2018 Session | George R. Buchanan Lectureship Award Presentation
  • 2018 Session | Plenary Paper Session 2001-2002
  • 2018 Session | St. Baldrick's Foundation Robert J. Arceci Innovation Award Announcement
  • 2018 Session | Plenary Session—Health Care in the Current Political Climate: Stormy Days Ahead?
  • 2018 Session | Pediatric Ependymoma: The Science Driving Patient Care
  • 2018 Session | Iron: Let's Get Pumped
  • 2018 Session | Extracellular Vesicle Trafficking—Biology and Translational Impact in Hematology and Cancer
  • 2018 Session | Relapsed, Refractory, Metastatic Bone Sarcomas: New Insights on Pathogenesis, Prognosis and Treatment
  • 2018 Session | Alpha Thalassemia—A Growing Public Health Disease with Changing Landscape of In-Utero and Post-Natal Therapy
  • 2018 Session | Decision Making in Benign Hematology: Living in a World Without Randomized Trials
  • 2018 Session | Northwestern Mutual Award for Excellence in Childhood Cancer Survivorship
  • 2018 Session | Early Career Travel Stipend Awards
  • 2018 Session | Young Investigator Award Presentations
  • 2018 Session | Management of Extracranial Germ Cell Tumors in Adolescent and Young Adult Population
  • 2018 Session | Challenging Hematologic Complications Post–Stem Cell Transplantation and Beyond
  • 2018 Session | Advanced Symptom Management and End-of-Life Care: Multidisciplinary Primary Palliative Care for Pediatric Hematologists/Oncologists
  • 2018 Session | Paper Session - Solid Tumor
  • 2018 Session | Paper Session - Hematology
  • 2018 Session | Vascular Anomalies: The Great Mimickers
  • 2018 Session | Addressing Sexual Health in Adolescent and Young Adult Patients: What You Should Know as a Pediatric Hematology/Oncology Care Provider
  • 2018 Session | Navigating Intravascular Bottlenecks: A Critical Mini-Review of Pediatric Venous Thromboembolism in the Setting of an Anatomical Thrombophilia
  • 2018 Session | Paper Session - Children's Oncology Group (COG)
  • 2018 Session | Paper Session - Hematology Science
  • 2018 Session | Can Late Effects be Prevented in Pediatric Oncology?
  • 2018 Session | Clash of the Titans: Debates on Best Management of Patients with Bleeding Disorders
  • 2018 Session | Providing Effective Feedback: The Currency of Conflict Resolution
  • 2018 Session | Recent Advances and New Approaches to Rare Hematological Malignancies
  • 2018 Session | Primary and Secondary Stroke Prevention in Sickle Cell Disease: The Debate
  • 2018 Session | Combating an Unmet Need: Psychosocial Health
  • 2018 Session | Renal Tumors Beyond Wilms
  • 2018 Session | Pediatric and Neonatal Transfusion Medicine
  • 2018 Session | Mobile Applications in Clinical Practice
  • 2018 Session | Presidential Symposium—Partnering with Patients and Families to Improve Research and Clinical Decision-making
  • 2018 Session | Review of Rare Pediatric Head and Neck Tumors for the General Oncologist
  • 2018 Session | Emerging Therapies in Hemophilia
  • 2018 Session | How Should You Treat That Bug? A Debate About Antimicrobial Management in Fever and Neutropenia
  • 2018 Session | Paper Session with Luminary Investigator - Leukemia
  • 2018 Session | Paper Session with Luminary Investigator - Hematology
  • 2018 Session | Frank A. Oski Memorial Lectureship Award Presentation
  • December 2018 eNews
  • 2019 Session | Splenectomy - The Great Debate
  • 2019 Session | DICER1: Updates on Biology and Clinical Management
  • 2019 Session | Burnout in Pediatric Hematology/Oncology: Moving from Discussion to Action
  • 2019 Session | Diagnostic and Management Conundrums Surrounding Women with Heavy Menstrual Bleeding and Underlying Bleeding Disorders
  • 2019 Session | All That Glitters is Not Gold – How We Differentiate Primary HLH from Fake News
  • Models for International Pediatric Oncology Outreach
  • 2019 Session | Navigating Genetic Testing in the Pediatric Hematology Setting
  • 2019 Session | Radiation Therapy for Pediatric Cancer Patients: Updates and New Modalities
  • 2019 Session | The Microbiome: What Is It and Why Do We Care?
  • 2019 Session | Brain Attack: Therapeutic Advances in Neonatal and Childhood Stroke
  • 2019 Session | Advances in Pediatric AML
  • 2019 Session | Improving Medication Adherence for Adolescents and Young Adults: Is Technology the Answer?
  • 2019 Session | Metabolism in Pediatric Hematology/Oncology - Presidential Symposium
  • 2019 Session | Too Much of a Good Thing – Myeloproliferation in Children
  • 2019 Session | Multiple Bony Lytic Lesions, but Not Langerhans Cell Histiocytosis (LCH) – Now What?
  • 2019 Session | Savior Siblings: Medical, Ethical, and Psychosocial Considerations in using Preimplantation Genetic Diagnosis (PGD) to Ensure a Matched Sibling Donor for Hematopoietic Stem Cell Transplantation (HSCT)
  • 2019 Session | George R. Buchanan Lectureship Award Presentation
  • 2019 Session | 2019 St. Baldrick’s Foundation Robert J. Arceci Innovation Award Announcement and Past Recipient Presentation
  • 2019 Session | Northwestern Mutual Award for Excellence in Childhood Cancer Survivorship Announcement and Frank A. Oski Memorial Lectureship Award Presentation
  • 2019 Session | New Paradigms for Severe Aplastic Anemia: Genetic Screening, Eltrombopag, and Up Front Unrelated Donor BMT
  • 2019 Session | Not Too Young for That Cancer: Adolescent and Young Adult Carcinomas
  • 2019 Session | Transforming the Treatment of Chronic Pain
  • 2019 Session | Putting an End to End Organ Damage in Sickle Cell Disease
  • 2019 Session | Defining Pediatric MDS: A Morphologic or Molecular Diagnosis?
  • 2019 Session | The Power of One: Present Challenges in Treating Rare Diseases
  • 2019 Session | Hematological Manifestations of Immune Deficiencies and Dysregulatory Disorders: When should you look harder for underlying causes of Autoimmune Cytopenias?
  • 2019 Session | Oncofertility Programs: More Than Just Sperm Banking
  • 2019 Session | The (Financial) Cost of a "Cure"
  • 2019 Session | (2001) Potential Utility of MRD to Identify Relapse in pALL Patients Treated with Tisagenlecleucel
  • 2019 Session | (2002) Lentiglobin Gene Therapy in Transfusion-Dependent Β-Thalassemia Patients with Non-β0/β0 Genotypes
  • 2019 Session | (2003) Mechanisms of Resistance to the Type II JAK2 Inhibitor CHZ868 in B-Cell Acute Lymphoblastic Leukemia
  • 2019 Session | (2004) Discovering Noncoding Genetic Elements that Regulate Globin Synthesis
  • 2019 Session | (2005) Emapalumab in Pediatric Patients with Primary Hemophagocytic Lymphohistiocytosis: Safety & Efficacy
  • 2019 Session | (2006) Modeling IKZF1 Lesions in B-cell Acute Lymphoblastic Leukemia Reveals Potential Therapeutic Targets
  • 2019 Session | (2007) Prognostic Determinants in Childhood T-cell Acute Lymphoblastic leukemia: Results of DFCI 05001
  • 2019 Session | (2008) Gap Junction Interference increases Apoptosis in ALL cells and augments effects of Antimetabolites
  • 2019 Session | (2009) Hydroxyurea Lowers Tricuspid Regurgitant Jet Velocity in Children with Sickle Cell Anemia
  • 2019 Session | (2010) Novel Next-Generation Sequence based Assay for Non-Invasive Prenatal Testing of Sickle Cell Disease
  • 2019 Session | (2011) Gabapentin for Pain in Sickle Cell Disease: Results of a Randomized Phase II Clinical Trial
  • 2019 Session | (2012) Quality of Life is the most important Indication for Second-Line ITP Treatment in Children
  • 2019 Session | (2013) BCL2-Inhibitor Response in Neuroblastoma: Biomarkers and Therapy Resistance
  • 2019 Session | (2014) The Clinical Application of Molecular Testing in Pediatric Solid Tumors: An Institutional Experience
  • 2019 Session | (2015) Enhancing Tumor Directed T Cells with an Interleukin-7 Signal Modulator
  • 2019 Session | (2016) Epigenome Screening Identifies Transcriptional Elongation as Therapeutic Vulnerability in DIPG
  • 2019 Session | (2017) Levofloxacin Prophylaxis
  • 2019 Session | (2018) Renal Tumors: Future Roadmap
  • 2019 Session | (2019) Soft Tissue Sarcoma
  • 2019 Session | (2020) Realizing Effectiveness across Continents with Hydroxyurea (REACH): A Prospective Multi-National Trial of Hydroxyurea for Sickle Cell Anemia in Sub-Saharan Africa
  • 2019 Session | (2021) Leucine for the Treatment of Transfusion Dependence in Patients with Diamond Blackfan Anemia
  • 2019 Session | (2022) A Phase 1/2 Trial of Investigational Spk-8011 in Hemophilia a Demonstrates Durable Expression and Prevention of Bleeds
  • 2019 Session | (2023) Peripherally Inserted Central Catheters (PICCs), the Leading Cause of Central Venous Catheter Associated Thrombosis in Children
  • 2019 Session | The Role of Survivorship Research in Advancing Childhood Cancer Care and Quality of Survival
  • 2019 Session | (2024) Septic Shock (SS) Incidence in National ALL & AML Cohorts using Administrative & Clinical Trial Data
  • 2019 Session | (2025) Nelarabine Abrogates Relapse Rates in CNS-3 T-ALL: A Report from Children’s Oncology Group AALL0434
  • 2019 Session | (2026) Current Cancer Survivorship Practices: A Report from the Children’s Oncology Group (COG)
  • 2019 Session | (2027) Intra-Arterial Chemotherapy for Retinoblastoma: A 7-year Single Institution Experience
  • 2019 Session | Advancing Discovery in Hematology: Bench to Bedside? No. Bedside to Bench to Bedside...
  • 2019 Session | (2028) The Shwachman Diamond Syndrome Registry: Hematologic Complications
  • 2019 Session | (2029) Characteristics and Outcomes of Unprovoked Venous Thromboembolism in the Pediatric Population
  • 2019 Session | (2030) Third Party VST are an effective Therapy for the Treatment of BK-Virus Reactivation after Transplant
  • 2019 Session | (2031) Inhibition of Nemo-Like Kinase improves Erythropoiesis in Models of Diamond Blackfan Anemia
  • 2019 Annual Meeting Session Recordings
  • CI SIG Webinar

eNews

Member Insights: eNews 2019 Highlights

This special eNews issue showcases member-authored Diversity Corner and Special Feature articles that appeared in 2019. Take a look back to appreciate the informative articles and personal reflections written by your colleagues.

Diversity Corner

April 2019

Embracing a Culture of Diversity
Betty S. Pace, MD

Diversity and inclusion (D&I) are guiding principles to build an organization that reflects its membership and celebrates multiple approaches and points of view. Strictly defined, diversity is the state of being diverse, or a range of different people who are actively engaged in an organization. In practical terms, it encompasses the understanding that individuals are unique and recognizes differences such as gender, sexual orientation, race, ethnicity, socio-economic status, and other ideologies (Ferrini-Mundy, 2013). The concept of D&I embraces acceptance and respect, building a culture where difference is valued, and taking a holistic approach. By establishing a consistent and logical foundation regarding differences, people are much more likely to have valuable and actionable conversations about specific kinds of differences such as race or gender. It is critical for organizations and institutions to make the endorsement of D&I an essential part of policies and procedures. Strengthening a D&I program will bring the best talent to an organization; supporting various voices will increase levels of creativity and productivity. There are numerous cultural barriers to the progression of marginalized groups to leadership in organizations and academic institutions, especially in Science, Technology, Engineering, Mathematics, and Medicine (STEMM). Recent approaches that incorporate “sponsorship programs” provide opportunity for effective interventions by creating roles for protégés, advocating for people within the organization, enabling new roles and opportunities, and making connections to senior leaders (Huston, Cranfield, Forbes, & Leigh, 2019). In today’s climate, members of organizations and academic institutions want to hear policies and plans to make diversity a reality.

The way organizations foster and nurture diversity is an important aspect of its culture. Diversity initiatives should not only be part of recruitment programs, but also be integrated into on-going workforce management and operations. This requires training staff to increase the support of diversity initiatives. Having a diverse workforce signals that the organization does not discriminate; that is, if an individual is qualified for the position, then he or she has a fair chance of getting it, no matter his or her background. We should strive to create organizations that reflect the communities we serve and where everyone feels empowered to bring their full, authentic selves to the table.

Having people from different lifestyles and backgrounds challenges the way others within the organization think, operate, and can catalyze innovation, insight, and adaptation. Additionally, it helps the organization to reach a wider membership and volunteer base because leadership can relate to more types of people. The major obstacle to implementing a diversity program is the challenges to evaluating its effectiveness. The tendency is to treat this as a subjective area, without clear metrics, analytics, or dashboards pointing towards areas of success and identifying those in need of improvement. There are many D&I tools commercially available—such as The Association Inclusion Index developed by the American Society of Association Executives (2019)—recently adopted by ASPHO to evaluate D&I initiatives within the organization. Embracing D&I is an ongoing process that requires constant commitment, evaluation, and process improvement. The ultimate goal is to build an inclusive culture that encourages, supports, and celebrates the diverse voices of our membership at-large.

ASPHO Diversity Statement:
ASPHO values and encourages diverse and inclusive participation within the profession of pediatric hematology/oncology. ASPHO is focused on attracting, developing, and retaining volunteers who reflect the diversity of its membership to play key roles in leading the Society. The Society seeks to create an atmosphere that encourages varied perspectives and participation in its committees, task forces, and board. ASPHO believes that an open exchange of ideas from diverse perspectives will result in improved decision making and will best serve our members' collective needs and interests and, by extension, those of their patients.

References

  1. Ferrini-Mundy, J. Science education (2013). Driven by diversity. Science, 340(6130), 278.
  2. Huston, W. M., Cranfield, C. G., Forbes, S. L., Leigh. A., (2019). A sponsorship action plan for increasing diversity in STEMM. Ecology and Evolution, 9(5), :2340–-2345.
  3. American Society of Association Executives. (2019). The Association Inclusion Index. Retrieved from https://www.asaecenter.org/about-us/diversity-and-inclusion/association-inclusion-index

 

June 2019

Diversity Special Interest Group: ASPHO 2019 Meeting Highlights and Future Endeavors
Pinki Prasad, MD MPH; Daniel Ortiz, MD; Kerice Pinkney, MD

Diversity SIG Mission
The ASPHO Diversity SIG (DSIG) aims to support the advancement of all ASPHO members and the field of pediatric hematology/oncology (PHO) through increasing diversity and inclusiveness in a broad sense in the membership and leadership of ASPHO as well as the home institutions of members. The DSIG has made it a top priority for our group’s activities to begin with early outreach where we connect medical students with faculty in the field of PHO at all of ASPHO’s national meetings.

The physician workforce continues to struggle with adequate representation of racial and ethnic minorities, with hematology and oncology lagging in medicine in general. According to the most recent census, 13% of the U.S. population is black or African American and 18% is Hispanic (United States Census Bureau, n.d.). In contrast, only 2.3% of practicing oncologists self-identified as black or African American and only 5.8% of practicing oncologists self-identified as Hispanic (Kirkwood et al, 2018; American Academy of Pediatrics, n.d.; Association of American Medical Colleges, n.d.). Individuals from populations that are underrepresented in medicine are even more underrepresented in oncology than in fellowship or residency programs in general. Thus, early outreach is essential for mentoring medical students and residents who are interested in PHO as a career choice.

LSUHSC Partnership
To further our commitment to mentoring, the DSIG collaborated with Louisiana State University Health Sciences Center (LSUHSC) to engage medical students and residents in the 2019 ASPHO Conference. We began with a meet and greet event the night before the conference. The School of Medicine at LSUHSC hosted the meet and greet under the faculty leadership of Dr. Cathy Lazarus, who is the associate dean of student affairs. The event included a presentation by Dr. Pinkney, 2018-2019 DSIG chair, on career pathways in PHO. This was followed by a question and answer session with Dr. Pinkney; Dr. Pinki Prasad, 2019-2020 DSIG chair; and Dr. Jennifer Krajewski. We also had a presentation from Jessica Briley, a representative of Be the Match, National Marrow Donor Program. Jessica discussed the ongoing efforts to increase the donor pool from diverse racial/ethnic communities and the importance of new partnerships with colleges and universities.

As part of our ongoing push to engage medical students and residents, the DSIG was able to partner with LSUHSC to provide sponsorship of five students and pediatric residents to attend the 2019 ASPHO Conference. At the conference, these selected medical students and residents were paired with faculty guides to help them navigate and answer questions regarding pursuing a career in academic PHO.

Challenges and Barriers to Women in Academic Medicine
Our keynote speaker for the 2019 DSIG workshop was Dr. Bonnie Desselle, vice chair of medical education at LSUSHC and Children’s Hospital of New Orleans, and the title of her talk was “Challenges and Barriers to Women in Academic Medicine.” Dr. Desselle highlighted an American Medical Association video,“Women in Medicine by Numbers”, showing that in 1860, there were roughly only 200 women physicians in the United States, and today, that number exceeds 376,000 (American Medical Association (AMA), n.d.). Despite the increase in women enrolling in medical school, leadership roles for women remain elusive. Less than 10% of women self-report as being a department head or a division chief (AMA, n.d.). In academic medicine, the proportion of women in higher academic ranks is lower than males across the country. The gender pay gap was discussed as studies have shown that women are offered lower pay and less institutional research funding when they join a faculty, and they continue to earn considerably less than men—even among those at the same level and with comparable productivity. The group was able to break out into small sessions to discuss why gender disparities exist and what institutions and physicians can do to help balance gender disparity. There was discussion at the end of the hour about formal mentoring and the importance of training and career development at all levels. The workshop was met with enthusiasm and received great feedback. We plan to incorporate this into a webinar in the upcoming months.

New Members
We welcome new members to join our DSIG. We communicate year-round using ASPHO’s online member community specifically for the DSIG.

References:

  1. American Academy of Pediatrics. Demographics of women physicians and pediatricians.
  2. American Medical Association. Women in medicine month. Retrieved from https://www.ama-assn.org/member-groups-sections/women-physicians/women-medicine
  3. Association of American Medical Colleges. Table 3. Distribution of U.S. medical school faculty by rank and race/ethnicity.
  4. Kirkwood, M. K., Hanley, A., Bruinooge, S. S., et al. (2018). The state of oncology practice in America, 2018: Results of the ASCO Practice Census survey. Journal of Oncology Practice, 14(7), e412-e420.
  5. United States Census Bureau. QuickFacts: United States. Retrieved from https://www.census.gov/quickfacts/table/PST045215/00.

Special Feature

February 2019

What Helps Us Do What We Do?
Mary Shapiro, MD

Shapiro Feb19 TCH20Breakthrough20Communications20Team 1When people hear that I am a pediatric hematologist/oncologist, I am frequently asked, “How do you do what you do? How do you handle those conversations with children who are so sick and their parents? I couldn’t do it.” I imagine that many of the people reading this article have had similar conversations with family, friends and colleagues. So how does each of us “do what we do?”

I know each of us has several answers to this question. One unique venture I wanted to share that helps me “do what we do” started almost 3 years ago, when I was asked if I wanted to be trained in relationship-centered patient communication. The day I said “yes” to this question changed my life. Our institution enlisted the Academy of Communication in Healthcare to train a handful of physicians and advanced practice providers in relationship-centered patient communication, specifically for a pediatric and women’s healthcare (obstetrics/gynecology) patient population. We now have our Texas Children’s Hospital (TCH) Breakthrough Communications Team which includes 13 faculty-trainers in various subspecialties who are charged with training the more than 1,200 pediatric and obstetric faculty at our hospital.

We teach three key skillsets in the form of brief didactics with interactive roleplay: skillset 1 focuses on initial rapport building with the patient/family and creating an agenda for the time spent together; skillset 2 focuses on reflective listening to patient/family perspectives, including ideas about diagnoses, fears, and expectations; and skillset 3 focuses on the provider sharing the assessment and collaborating with the patient/family to create the plan. Lessons about the importance of the provider expressing empathy are interwoven throughout each of these skillsets. We term the cumulative product “our communication toolbox.” We also use specific feedback in each workshop to reinforce the individual’s most effective approaches and fine-tune approaches that have room for improvement. I have been privileged to watch countless faculty successfully work through very challenging communication scenarios over the years.

Participating in our TCH Breakthrough Communications Team has given me the invaluable opportunity to teach a unique communication toolbox to providers across subspecialties and stages in their careers. The personal use of these skills also continues to improve my own communication and relationships with my patients and colleagues. These experiences actually have taught me just as much as any book or mentor in my medical career, and they have been a huge part of how I “do what I do” every day with eager hands and a heart fulfilled. I urge each of you to seize any similar opportunity that may come your way; the result of taking that opportunity may render more reward than you can imagine!

August 2019

A Friendly Reminder, from a Fellow’s Perspective
Marjilla Seddiq, MD

Every now and then you need a friendly reminder about the things that excite, motivate, and encourage you to carry on. At the start of pediatric hematology/oncology fellowship all the reasons why you chose to dedicate 3 more years of your life to training are fresh in your mind. You remember bonding over pumpkin pie with your 11-year-old male patient diagnosed with acute lymphoblastic leukemia who had to spend Thanksgiving in the hospital, the mother you reassured when her newborn was diagnosed with sickle cell disease (which back home in Nigeria would have given her no hope for a fruitful life), and the new and exciting research taking place and the idea that you could be a part of it.

Then fellowship begins, and along with this new start comes a steep learning curve, new responsibilities, and a neverending checklist. Within the everyday hustle of juggling the consulting and inpatient services, you slowly forget those things that once inspired and excited you. Instead, your mind is occupied with tumor lysis lab results, Children’s Oncology Group protocols, chemotherapy orders, and sleepless nights interrupted by the disharmonious sounds of a pager.

At some point in that first year, though, you are presented with a patient diagnosed with a new and rare condition. That bond you cherished begins to form with your new patient. Intellectually, you are reinvigorated and feel the need to share this energy with the pediatric hematology/oncology community, as I did in New Orleans at the 2019 ASPHO Conference. This provided me the invaluable opportunity to gain experience from constructing a poster, presenting it in a professional forum, and attending stimulating, intellectually driven seminars.

The ASPHO Conference is a place where you can step away from that checklist and press the refresh button. Two wonderful aspects of the conference were the educational session on models for international pediatric oncology outreach and the distinguished career award presentation, which honored Dr. Elliott Vichinsky.

aspho conference

The educational session regarding international outreach reminded me of my past volunteer work and provided exposure to the work my colleagues are doing. It was uplifting to see the joint efforts between American and foreign oncology groups to better the quality of life and outcomes of patients on a global scale. It was even more encouraging to know that I too can be a part of this.

The Distinguished Career Award presented to Dr. Elliott Vichinsky was moving. As the slideshow showcased the start of Dr. Vichinsky’s career, his work within the sickle cell community, and his personal accomplishments, the wave of inspiration rippling through the audience was palpable. To see the impact that one person can have on his patients, colleagues, and community was powerful. It reminded me that the checklists and the countless pages all contribute to a greater effort and cause. They contribute to me becoming the best version of myself for those lives that matter the most—the lives of my patients.

Among fellows, especially within the first year, there can be a fear that a part of who we are will be lost in the everyday workload and that what we love about the field becomes buried and may never resurface. Attending a conference like ASPHO’s allows you, layer by layer, to come back to the surface and breathe. It reminds you of your passions, who you are, and why you carry on.

 

December 2019

The Evolving Paradigm of Developmental Therapeutics
Kate Mazur, MSN APRN CPNP

“All of your patients will die.” Those were the words that were said to me on my first day on the job. Young and fresh out of graduate school, I was scared and nervous, but eager to learn and develop my skills as a practitioner. I didn’t seek out a position in developmental therapeutics, but it was the opportunity that presented itself, and over the next 10 years I would learn that it was the position that was truly meant for me.

Although the expectation of success of Phase 1 clinical trials was set low for me from the beginning, the next 10 years would be a whirlwind of change in the world of pediatric oncology. In the short timeframe of my career, I have seen early phase clinical trials evolve from utilization of cytotoxic chemotherapy in all types of cancers to development of targeted agents for broad indications to the current landscape of “precision” or “personalized” medicine. Once only a thing of science-fiction movies, personalized medicine is as close to reality today as it has ever been.

I am awed and inspired at the state of current pediatric research. In this new era of pediatric oncology, the knowledge of tumor heterogeneity, advancements in cancer biology, and improvements in disease modeling have led to compelling new opportunities for therapeutic approaches tailored to individual patients. Ever-increasing numbers of clinical trials are developed with agents targeting a particular tumor marker or mutation and given to individual patients known to harbor that molecular aberration. Although efficacy of many of these new agents is still under study, the promise of early phase clinical trial success is vastly enhanced as we increasingly utilize the biological basis of a tumor or individual’s genome to guide therapeutic choice.

In addition to molecularly targeted novel agents, the emergence of immunotherapy has also transformed developmental therapeutics. The concept of harnessing the body’s own immune system to fight cancer is not a new one, but not until recently was it translated into clinical practice at such an expeditious rate. Through the use of treatment modalities such as tumor vaccines, cellular therapies, and immune-stimulatory agents, immunotherapy has catapulted into the forefront of childhood cancer drug development.

As a result of an enriched understanding of tumor biology and innovative treatment strategies, cancer drug development has seen unprecedented progress and opportunity over the past decade. As I think back to those words said to me on my first day on the job, I am reminded of how much things have evolved since then. It is not uncommon for patients who enter Phase 1 clinical trials to have prolonged stability, objective tumor response, or even long-term survival with these innovative new therapies. It is an exciting time to be a practitioner in the field of developmental therapeutics, and I eagerly await the future progress of pediatric oncology treatment.

 

Copyright© 2020 by the American Society of Pediatric Hematology/Oncology. All rights reserved. The views and opinions expressed in the Feature Articles are those of the author alone and do not imply an opinion on the part of ASPHO, its Board of Trustees or staff. The information in this newsletter is intended to provide readers with resources and information that they may find useful and of interest and is only current as of the publication date. ASPHO is not liable to any party as a result of their reliance on the information, recommendations, services, or resources discussed or made available through this newsletter.

Advertising, Exhibits, & Support | Career Center | Calendar | Contact Us
Terms of Use & Privacy Policy » © The American Society of Pediatric Hematology/Oncology